Low Levels of Pepsinogen I and Pepsinogen I/II Ratio are Valuable Serologic Markers for Predicting Extensive Gastric Corpus Atrophy in Patients Undergoing Endoscopic Mucosectomy
2
조회
0
다운로드
5
인용
0
참고문헌
초록
Background/Aims: The levels of pepsinogen (PG) I and the PGI/II ratio are useful serologic markers for chronic atrophic gastritis. This study evaluated the performance and clinical implications of these markers in patients undergoing endoscopic mucosectomy. Methods: We enrolled 142 consecutive patients with early gastric tumors and Helicobacter pylori infection who were eligible for mucosectomy. Chronic gastritis and atrophy were assessed using four defined biopsy procedures. Serum PGs were measured by an enzyme immunoassay. Optimal diagnostic cut-offs and performance were determined using receiver operating characteristic curves. Results: The PGI level and the PGI/II ratio decreased with corpus-dominant gastritis and as atrophy advanced toward the corpus greater curvature (GC). For the presence of corpus GC atrophy,the areas under the PGI and PGI/II-ratio curves were 0.82 and 0.77, respectively. The optimal cut-off levels were 59.3μg/L for PGI (sensitivity, 83.3%; specificity,78.4%) and 3.6μg/L for PGI/II ratio (sensitivity,70.0%; specificity, 78.4%). Using these serologic cut-off levels, we found that the frequency of corpus tumor location differed significantly (32.9% vs 11.1%for PGI ＜59.3 and ≥59.3μg/L, respectively; and 31.1%vs 14.8% for PGI/II ratio ＜3.5 and ≥3.5, respectively;p＜0.05). Conclusions: A low PGI level and PGI/II ratio are valuable serologic markers for predicting corpus GC atrophy, and have clinical implications with respect to the corpus location of tumors in mucosectomy patients.
Abstract
Background/Aims: The levels of pepsinogen (PG) I and the PGI/II ratio are useful serologic markers for chronic atrophic gastritis. This study evaluated the performance and clinical implications of these markers in patients undergoing endoscopic mucosectomy. Methods: We enrolled 142 consecutive patients with early gastric tumors and Helicobacter pylori infection who were eligible for mucosectomy. Chronic gastritis and atrophy were assessed using four defined biopsy procedures. Serum PGs were measured by an enzyme immunoassay. Optimal diagnostic cut-offs and performance were determined using receiver operating characteristic curves. Results: The PGI level and the PGI/II ratio decreased with corpus-dominant gastritis and as atrophy advanced toward the corpus greater curvature (GC). For the presence of corpus GC atrophy,the areas under the PGI and PGI/II-ratio curves were 0.82 and 0.77, respectively. The optimal cut-off levels were 59.3μg/L for PGI (sensitivity, 83.3%; specificity,78.4%) and 3.6μg/L for PGI/II ratio (sensitivity,70.0%; specificity, 78.4%). Using these serologic cut-off levels, we found that the frequency of corpus tumor location differed significantly (32.9% vs 11.1%for PGI ＜59.3 and ≥59.3μg/L, respectively; and 31.1%vs 14.8% for PGI/II ratio ＜3.5 and ≥3.5, respectively;p＜0.05). Conclusions: A low PGI level and PGI/II ratio are valuable serologic markers for predicting corpus GC atrophy, and have clinical implications with respect to the corpus location of tumors in mucosectomy patients.
참고문헌 (27)
- Suzuki H, "Helicobacter pylori: present status and future prospects in Japan", J Gastroenterol, 42, pp.1~15 (2007)
- Suzuki H, "Helicobacter pylori and gastric cancer", Gastric Cancer, 12, pp.79~87 (2009)
- Fock KM, "Asia-Pacific consensus guidelines on gastric cancer prevention", J Gastroenterol Hepatol, 23, pp.351~365 (2008)
- Uemura N, "Helicobacter pylori infection and the development of gastric cancer", N Engl J Med, 345, pp.784~789 (2001)
- Wong BC, "Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial", JAMA, 291, pp.187~194 (2004)
- Rugge M, "Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading", Aliment Pharmacol Ther, 16, pp.1249~1259 (2002)
- Broutet N, "Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics", Br J Cancer, 88, pp.1239~1247 (2003)
- Korstanje A, "Comparison between serology and histology in the diagnosis of advanced gastric body atrophy: a study in a Dutch primary community", J Clin Gastroenterol, 42, pp.18~22 (2008)
- Watabe H, "Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study", Gut, 54, pp.764~768 (2005)
- Ohata H, "Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer", Int J Cancer, 109, pp.138~143 (2004)
- Sergio Coda, "Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection as Treatments for Early Gastrointestinal Cancers in Western Countries", Gut and Liver, 1(1), pp.12~21 (2007), 거트앤리버 발행위원회
- Park DI, "Risk factors suggesting malignant transformation of gastric adenoma: univariate and multivariate analysis", Endoscopy, 33, pp.501~506 (2001)
- Lauwers GY, "Defining the pathologic diagnosis of metaplasia, atrophy, dysplasia, and gastric adenocarcinoma", J Clin Gastroenterol, 36, pp.S37~S43 (2003)
- Choi KD, "Application of metal hemoclips for closure of endoscopic mucosal resection-induced ulcers of the stomach to prevent delayed bleeding", Surg Endosc, 22, pp.1882~1886 (2008)
- Kim JJ, "EMR for early gastric cancer in Korea: a multicenter retrospective study", Gastrointest Endosc, 66, pp.693~700 (2007)
- Graham DY, "Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America", Clin Gastroenterol Hepatol, 4, pp.306~314 (2006)
- Ricuarte O, "Atrophic gastritis in young children and adolescents", J Clin Pathol, 58, pp.1189~1183 (2005)
- Sipponen P, "Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers", Scand J Gastroenterol, 42, pp.2~10 (2007)
- Varis K, "Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group", Scand J Gastroenterol, 35, pp.950~956 (2000)
- Miki K, "Gastric cancer screening using the serum pepsinogentest method", Gastric Cancer, 9, pp.245~253 (2006)
- Fiorucci S, "Nitric oxide modulates pepsinogen secretion induced by calcium-mediated agonist in guinea pig gastric chief cells", Gastroenterology, 109, pp.1214~1223 (1995)
- Kang JM, "The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea", Helicobacter, 13, pp.146~156 (2008)
- Lorente S, "Helicobacter pylori stimulates pepsinogen secretion from isolated human peptic cells", Gut, 50, pp.13~18 (2002)
- Miki K, "Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method", Am J Gastroenterol, 98, pp.735~739 (2003)
- Ono H, "Endoscopic mucosal resection for treatment of early gastric cancer", Gut, 48, pp.225~229 (2001)
- Correa P, "Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention", Cancer Res, 52, pp.6735~6740 (1992)
- El-Zimaity HM, "Patterns of gastric atrophy in intestinal type gastric carcinoma", Cancer, 94, pp.1428~1436 (2002)